Enriched Clinical Trial Design: Who Gets Left Behind?
Enriched clinical trial design can improve trial efficiency, but may exclude patients from the evidence base. Explore the implications for clinical development.
“The pharma industry is beginning to look at biological age as a surrogate endpoint to improve clinical trials."
Explore expert-led podcasts, pharmaceutical intelligence, life sciences insights and research-driven analysis from leading industry voices. Pharmatica delivers trusted biotech news, drug development trends and commercial intelligence for professionals across the pharmaceutical sector.
Enriched clinical trial design can improve trial efficiency, but may exclude patients from the evidence base. Explore the implications for clinical development.
Discover how predictive modelling, QSP, AI, and systems biology creates better drug development by connecting biological evidence with better predictions.
EHR patient recruitment could improve clinical trial matching, but workflow integration, data quality, interoperability, and AI validation remain key challenges.
Find out how q-CAR drug discovery moves beyond static protein structures by linking protein dynamics, ligand activity, and AI to precision drug design.
Ethical obligations in decentralised clinical trials extend beyond consent and privacy. Sponsors must protect safety, scientific validity, equity, and oversight.
Ocular drug delivery faces major biological barriers. Nanocarriers could improve bioavailability, tissue targeting, controlled release, and treatment for difficult eye diseases.
Adaptive clinical trials can improve efficiency, reduce patient burden, and support faster development through structured, evidence-based flexibility.
Collaboration in drug discovery can shape pharma R&D success. Explore the evidence on pharma partnerships, knowledge sharing, governance, and innovation.
Patient and public involvement in clinical trials improves study design. Learn why better reporting is essential for transparent, patient-centred research.
Find out how psychedelic drug discovery is evolving through receptor pharmacology, behavioural science, and neuroplasticity to develop safer CNS therapeutics.
A recent systematic review reveals incredible detail about informed consent in clinical trials, participant understanding, and trial quality. Find out now.
Read about machine learning for lipid nanoparticle design used to improve cell, gene, and RNA drug delivery and help optimise next-generation therapeutics.